Clinical Trial Update: A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial of SHR-1210 (an anti-PD-1) combined with hypofractionated radiotherapy in non-small cell lung cancer (NSCLC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SHR-1210 (camrelizumab)

Snippet

Sponsor: Shandong Cancer Hospital and Institute | Conditions: Non-Small-Cell Lung Cancer | Phase 2 | Status: UNKNOWN